Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.62 |
| ▸ | MAPT | P10636 | 16/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22095278 | 0.88 | LMNA (0.67) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928561 | 0.87 | NPSR1 (0.63) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928552 | 0.87 | LMNA (0.69) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928691 | 0.85 | NPSR1 (0.60) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928680 | 0.85 | NPSR1 (0.63) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928497 | 0.83 | LMNA (0.78) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22095364 | 0.82 | NPSR1 (0.62) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2463380 | 0.82 | DCTPP1 (0.67) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23928601 | 0.81 | DCTPP1 (0.67) | LMNANPSR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL12684718 | 0.80 | ALDH1A1 (0.82) | LMNANPSR1ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | LMNA 1751/4885NPSR1 3150/4885ALDH1A1 1/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | LMNA 1751/4885NPSR1 3150/4885ALDH1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.